You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Despite recognition among drugmakers, researchers, and regulators of the need to diversify precision oncology trials, few Black and Hispanic patients are included in studies.
The field is collecting evidence supporting genomics-guided care but experts are still awaiting prospective data and grappling with other challenges.
The software firm will use NGS data from patient biopsies to create molecular profiles and offer individualized cancer treatment recommendations.
Practical, technological, and systemic challenges are putting pathologists in tough positions, facing competing demands for molecular analysis of limited biological samples.
Chi Van Dang discussed major breakthroughs now moving out into community practice, continued challenges, and promising new areas oncologists may want to watch.
Investigators from a variety of clinical sites found that the company's liquid biopsy test was more successful in finding actionable mutations in patients than tumor tissue.
Japanese software giant NEC invests in AI-centric software company BostonGene to advance immuno-oncology and other targeted cancer treatments.
The company said it will seek FDA approval for the assay, an expanded version of FoundationACT, as a CDx for targeted therapies and as a tumor mutation profiling assay.
Foundation Medicine will provide genomic profiling for the EORTC's Screening Patients for Efficient Clinical Trial Access program.
At the AACR annual meeting, researchers presented results from the Phase II SUMMIT trial investigating the pan-HER-targeted therapy neratinib.